Locteron: Additional Phase IIb data

Additional data from the international Phase IIb SELECT-2 trial in 116 treatment-naïve HCV patients showed that a greater proportion of patients receiving 320, 480 and 640 µg subcutaneous Locteron every other week achieved an SVR 12 weeks after the end of the 48-week treatment period vs. 1.5 µg/kg PEG-Intron peginterferon alfa-2b (36%, 35% and 45%, respectively, vs. 30%). Low-, mid- and high-dose Locteron also led to significant reductions in flu-like adverse events of 71%, 68% and 69%, respectively, compared to PEG-Intron (p<0.001 for all). Additionally, fewer patients receiving low-, mid- and high-dose Locteron used analgesics and antipyretics vs. PEG-Intron (45%, 48% and 66%, respectively, vs. 73%). Furthermore, 14%, 21% and 34% of patients receiving low-, mid- and high-dose Locteron, respectively, reported BDI scores >16, which indicates mild depression, vs. 37% for PEG-Intron. All patients also received ribavirin. ...